证券代码：002817 证券简称：黄山胶囊 安徽黄山胶囊股份有限公司 2025 年度独立董事述职报告（王清华） 各位股东及代表： 作为安徽黄山胶囊股份有限公司（以下简称"公司"）的独立董事，本人依 据《公司法》《证券法》《上市公司治理准则》《上市公司独立董事管理办法》等 法律法规、规范性文件的要求，以及《公司章程》《独立董事工作制度》的有关 规定，本着客观、公正、独立的原则，忠实、勤勉履行职责，积极出席相关会议， 认真审议董事会各项议案，充分发挥了独立董事及各专门委员会的作用，维护公 司及全体股东的利益。现将 2025 年度履行职责的情况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景及兼职情况 本人王清华：女，汉族，1974 年 3 月出生，安徽师范大学中文系学士、复 旦大学国际经济法学双学士、英国曼彻斯特大学国际商法硕士、美国加州大学伯 克利分校访问学者、上海交通大学国际环境法学博士。曾就职上海市国耀律师事 务所，现任国际律师协会中国工作委员会成员、第五届武汉仲裁委员会仲裁员、 第四届合肥仲裁委员会仲裁员、上海民建社会经济发展研究院法治研究所所长、 上海贸促国际商事调解中心调解员、上海市锦天城 ...

安徽黄山胶囊股份有限公司 关联交易决策制度 安徽黄山胶囊股份有限公司 关联交易决策制度 第三条 公司的关联人包括关联法人（或者其他组织）和关联自然人。 二〇二六年三月 1 安徽黄山胶囊股份有限公司 第四条 具有以下情形之一的法人或者其他组织，为公司的关联法人（或者 2 关联交易决策制度 第一条 为规范安徽黄山胶囊股份有限公司（以下简称"公司"）的关联交易 决策事宜，依据中国证监会《上市公司治理准则》、深圳证券交易所（以下简称 "深交所"）《股票上市规则》等法律、法规、规范性文件和《公司章程》的有关 规定，结合本公司实际情况，制订本制度。 第二条 公司的关联交易是指公司及公司的控股子公司与公司关联人之间发 生的转移资源或者义务的事项，包括但不限于以下交易： （一）购买或者出售资产； （二）对外投资（含委托理财、对子公司投资等）； （三）提供财务资助（含委托贷款等）； （四）提供担保（含对控股子公司担保等）； （五）租入或者租出资产； （六）委托或者受托管理资产和业务； （七）赠与或者受赠资产； （八）债权、债务重组； （九）签订许可协议； （十）转让或者受让研发项目； （十一）放弃权利（含放弃优先购买权、优先认 ...

证券代码：002817 证券简称：黄山胶囊 安徽黄山胶囊股份有限公司 2025 年度独立董事述职报告（曹钟勇） 各位股东及代表： 作为安徽黄山胶囊股份有限公司（以下简称"公司"）的独立董事，本人严 格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董事管理办法》 等法律法规、规范性文件以及《公司章程》《独立董事工作制度》的有关规定， 忠实、勤勉、独立地履行职责，积极出席相关会议，认真审议各项议案，充分发 挥了独立董事及各专门委员会的作用，维护公司整体利益及全体股东的合法权益。 本人于 2025 年 12 月 18 日就任公司第六届董事会独立董事，现将 2025 年度 履行职责的情况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景及兼职情况 （二）不存在影响独立性的情况说明 2025 年度任职期间，本人不在公司担任除独立董事以外的其他职务，与公 司及其主要股东不存在直接或间接利害关系，或者其他可能影响本人进行独立客 观判断的关系。本人符合各项监管规定中对于出任公司独立董事所应具备的独立 性要求，能够独立、公正地履行职责，不受公司及其主要股东等单位或个人的影 响。 2025 年度，本人对独立 ...

证券代码：002817 证券简称：黄山胶囊 安徽黄山胶囊股份有限公司 2025 年度独立董事述职报告（沙风） 各位股东及代表： 本人作为安徽黄山胶囊股份有限公司（以下简称"公司"）第五届董事会独 立董事，严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立 董事管理办法》等法律法规、规范性文件的要求，以及《公司章程》《独立董事 工作制度》的有关规定，忠实勤勉地履行独立董事职责，出席董事会、各专门委 员会和股东会会议，充分发挥独立董事的作用，监督公司规范化运作，维护公司 股东尤其是中小股东的合法权益。 本人因连任公司两届独立董事，于 2025 年 12 月公司第六届董事会换届后离 任，不再担任公司董事会独立董事及各专门委员会相关职务。现将本人 2025 年 度任职期间的工作情况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景及兼职情况 本人沙风，男，汉族，1970 年 3 月出生，中国国籍，无境外永久居留权， 硕士研究生学历。曾任职于安徽省宣城市中级人民法院、上海北方事务所、上海 君悦律师事务所；现任安徽敬亭山律师事务所律师，合伙人，香农芯创科技股份 有限公司独立董事，2021 年 1 月 ...

董事、高级管理人员薪酬管理制度 安徽黄山胶囊股份有限公司 董事、高级管理人员薪酬管理制度 $$\Xi{\bf O}\Xi\lambda\Phi\Xi\beta$$ 安徽黄山胶囊股份有限公司 1 安徽黄山胶囊股份有限公司 董事、高级管理人员薪酬管理制度 第一章 目的 第一条 为完善公司治理结构，规范安徽黄山胶囊股份有限公司（以下简称 "公司"）董事、高级管理人员的薪酬管理，建立科学有效的激励与约束机制， 充分调动董事、高级管理人员（以下简称"高管"）的积极性和创造性，促进公 司健康和可持续发展，根据《中华人民共和国公司法》、《上市公司治理准则》、 《安徽黄山胶囊股份有限公司章程》（以下简称"《公司章程》"）等法律法规及规 范性文件，结合公司实际情况，特制定本制度。 第二章 适用范围 第二条 本制度适用对象为公司董事、高管，具体包括以下人员： （一）董事：包括独立董事和非独立董事（含职工代表董事）； （二）高级管理人员：指《公司章程》中注明的公司总经理、副总经理、董 事会秘书、财务总监和董事会认定的其他高级管理人员。 第三章 管理原则 第三条 以公司经营经济指标和综合管理为基础，根据公司年度经营计划和 分管工作的 ...

证券代码：002817 证券简称：黄山胶囊 安徽黄山胶囊股份有限公司 2025 年度独立董事述职报告（赵西卜） 各位股东及代表： 作为安徽黄山胶囊股份有限公司（以下简称"公司"）的独立董事，本人依 据《公司法》《证券法》《上市公司治理准则》《上市公司独立董事管理办法》等 法律法规、规范性文件的要求，以及《公司章程》《独立董事工作制度》的有关 规定，恪尽职守，勤勉尽责，积极出席相关会议，认真审议各项议案，及时了解 公司经营信息，全面关注公司的发展情况，忠实履行了独立董事的职责，切实维 护公司整体利益及全体股东的合法权益。现将 2025 年度履行职责情况述职如下： 本人赵西卜，男，汉族，1963 年 10 月生，民建会员，博士研究生学历，经 济学博士，管理学博士后，中国注册会计师，中国人民大学商学院会计学系教授， 博士研究生导师。历任中国企业会计准则委员会咨询专家、政府会计准则委员会 咨询专家、全国预算与会计研究会智库专家，南京熊猫电子股份有限公司财务总 监等。现任中国融通财产保险有限公司独立董事、北京京管泰富基金管理有限公 司独立董事、北京首都在线科技股份有限公司独立董事、深圳紫光同创电子股份 有限公司独立董事 ...

安徽黄山胶囊股份有限公司 对外投资决策制度 安徽黄山胶囊股份有限公司 对外投资决策制度 二〇二六年三月 1 安徽黄山胶囊股份有限公司 对外投资决策制度 第一章 总则 第一条 为规范公司及公司控股子公司的投资行为，降低投资风险，提高投 资收益，根据《中华人民共和国公司法》（以下简称"《公司法》"）等国家有关法 律、法规及《安徽黄山胶囊股份有限公司章程》（以下简称"《公司章程》"）的相 关规定，制定本制度。 第二条 本制度所指对外投资或投资仅指权益性投资。 权益性投资包括各项股权投资、债权投资、产权交易、公司重组以及合资合 作等。 重大资本性支出如购置消费类资产（如车辆）、超过年度经营计划的技术改 造、基本建设、重大固定资产购置等不在本制度规范之内。 第三条 投资管理遵循的基本原则为：符合公司发展战略，合理配置企业资 源，促进要素优化组合，创造良好经济效益。 第二章 投资决策和管理机构 （一）根据公司经营目标和发展规划编制并指导实施投资计划； （二）对投资项目的预选、策划、论证及实施进行管理与监督； （三）负责跟踪分析新增投资企业或项目的运行情况； （四）与公司财务管理部门共同参与投资项目终（中）止清算与交接工作 ...

关于使用闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 重要内容提示： 1、投资种类：使用闲置自有资金投资本金保本型存款和固定收益凭证。 2、投资金额：公司拟使用不超过 55,000 万元闲置自有资金进行现金管理。 3、特别风险提示：公司在开展闲置自有资金现金管理过程中存在市场波动、 实际收益不可预期等风险，公司将积极落实内部控制制度和风险防范措施，敬请 投资者注意投资风险。 一、投资情况概述 （一）投资目的 为提高公司资金的使用效率，在确保不影响公司日常经营运作资金需求、有 效控制投资风险的前提下，公司拟利用自有资金进行现金管理，增加存量资金收 益。 证券代码：002817 证券简称：黄山胶囊 公告编号：2026-003 安徽黄山胶囊股份有限公司 自公司董事会审议通过之日起十二个月内有效。 （五）资金来源 （二）投资金额 公司拟使用不超过 55,000 万元闲置自有资金进行现金管理，在上述授权额 度范围内计划购买安全性高、流动性好且期限不超过 36 个月的本金保本型存款 和固定收益凭证，在投资期限内，上述投资金额可循环滚动使 ...

Group 1 - Huangshan Capsule's stock price has increased for seven consecutive days, with a cumulative rise of 5.98%, but experienced a decline of 2.59% on February 12 [1] - The stock price fluctuated significantly over the past seven trading days, with a closing price of 8.37 yuan on February 6, peaking at 8.53 yuan on February 11, and dropping to 8.29 yuan on February 12, resulting in a price range fluctuation of 2.99% [2] - The main business of Huangshan Capsule includes gelatin hollow capsules and enteric-coated gelatin hollow capsules, indicating a stable revenue structure [1] Group 2 - Institutional interest in Huangshan Capsule is relatively low, with a fund holding ratio of only 0.03% and a low ranking in industry research frequency, with ratings being neutral [3] - The earnings forecast for 2024 indicates an expected earnings per share of 0.16 yuan, with a projected net profit decline of 24.07%, suggesting limited improvement in fundamentals [3]

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]